PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-0.21
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.21. Seth Klarman would scrutinize path to profitability versus peers.
3.59
P/S near Drug Manufacturers - Specialty & Generic median of 3.59. Charlie Munger would examine if similar pricing reflects similar economics.
0.24
P/B less than half the Drug Manufacturers - Specialty & Generic median of 0.59. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-33.09
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-115.89
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 2.59. Seth Klarman would investigate operational improvement potential.
0.24
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.59. Joel Greenblatt would investigate if this discount is justified.
-118.24%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -7.12%. Seth Klarman would investigate path to profitability.
-3.02%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.